Bionano Genomics Inc. [NASDAQ: BNGO] slipped around 0.0 points on Wednesday, while shares priced at $0.49 at the close of the session, down -0.33%. The company report on November 19, 2020 that Bionano Genomics and its Users Present the Saphyr System for Optical Genome Mapping and Various Advancements in Clinical Variant Detection at AMP 2020.
Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the performance and application of its Saphyr system for optical genome mapping are being showcased at the Annual Meeting of the Association for Molecular Pathology (AMP), being held virtually at amp20.amp.org from November 16-20. AMP is widely recognized as the preeminent scientific society dedicated to advancing the clinical practice, science and excellence of molecular and genomic laboratory medicine. With over 2,500 members in over 50 countries working in the field of molecular pathology, its annual meeting is considered the prime event for presenting advances and technological innovations in molecular diagnostics to pathologists, laboratory directors and clinical professionals.
The Annual Meeting of AMP carries an educational component that teaches pathologists and laboratory professionals about novel and emerging methods in molecular pathology. For the first time at the meeting this year, Bionano optical genome mapping was taught as a technique in molecular pathology in the Get AMPed! Virtual Course on testing modalities for genome structure analysis along with current standard of care methods such as karyotyping, FISH and microarray analysis.
Bionano Genomics Inc. stock is now -60.56% down from its year-to-date (YTD) trading value. BNGO Stock saw the intraday high of $0.4988 and lowest of $0.4872 per share. The company’s 52-week high price is 1.39, which means current price is +95.60% above from all time high which was touched on 01/02/20.
Compared to the average trading volume of 5.46M shares, BNGO reached a trading volume of 4163005 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Bionano Genomics Inc. [BNGO]?
Ladenburg Thalmann have made an estimate for Bionano Genomics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 24, 2020. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on April 08, 2020, representing the official price target for Bionano Genomics Inc. stock.
The Average True Range (ATR) for Bionano Genomics Inc. is set at 0.03, with the Price to Sales ratio for BNGO stock in the period of the last 12 months amounting to 9.93. The Price to Book ratio for the last quarter was 4.45, with the Price to Cash per share for the same quarter was set at 0.13.
How has BNGO stock performed recently?
Bionano Genomics Inc. [BNGO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.99. With this latest performance, BNGO shares dropped by -7.72% in over the last four-week period, additionally plugging by 8.91% over the last 6 months – not to mention a drop of -47.48% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNGO stock in for the last two-week period is set at 41.60, with the RSI for the last a single of trading hit 40.33, and the three-weeks RSI is set at 42.59 for Bionano Genomics Inc. [BNGO]. The present Moving Average for the last 50 days of trading for this stock 0.5577, while it was recorded at 0.5017 for the last single week of trading, and 0.5735 for the last 200 days.
Bionano Genomics Inc. [BNGO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Bionano Genomics Inc. [BNGO] shares currently have an operating margin of -255.44 and a Gross Margin at +22.46. Bionano Genomics Inc.’s Net Margin is presently recorded at -294.34.
Return on Total Capital for BNGO is now -120.73, given the latest momentum, and Return on Invested Capital for the company is -261.76. Return on Equity for this stock declined to -433.64, with Return on Assets sitting at -108.40. When it comes to the capital structure of this company, Bionano Genomics Inc. [BNGO] has a Total Debt to Total Equity ratio set at 555.80. Additionally, BNGO Total Debt to Total Capital is recorded at 84.75, with Total Debt to Total Assets ending up at 66.49.
Reflecting on the efficiency of the workforce at the company, Bionano Genomics Inc. [BNGO] managed to generate an average of -$307,372 per employee. Receivables Turnover for the company is 1.87 with a Total Asset Turnover recorded at a value of 0.37.Bionano Genomics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.20.
Earnings analysis for Bionano Genomics Inc. [BNGO]
With the latest financial reports released by the company, Bionano Genomics Inc. posted -0.3/share EPS, while the average EPS was predicted by analysts to be reported at -0.18/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -66.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BNGO.
Insider trade positions for Bionano Genomics Inc. [BNGO]
There are presently around $4 million, or 5.50% of BNGO stock, in the hands of institutional investors. The top three institutional holders of BNGO stocks are: VANGUARD GROUP INC with ownership of 5,566,305, which is approximately 1468.977% of the company’s market cap and around 0.06% of the total institutional ownership; BANK JULIUS BAER & CO. LTD, ZURICH, holding 849,999 shares of the stock with an approximate value of $0.42 million in BNGO stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $0.3 million in BNGO stock with ownership of nearly 91.937% of the company’s market capitalization.
Positions in Bionano Genomics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 20 institutional holders increased their position in Bionano Genomics Inc. [NASDAQ:BNGO] by around 6,363,848 shares. Additionally, 11 investors decreased positions by around 1,905,130 shares, while 2 investors held positions by with 122,473 shares. The mentioned changes placed institutional holdings at 8,391,451 shares, according to the latest SEC report filing. BNGO stock had 10 new institutional investments in for a total of 627,463 shares, while 6 institutional investors sold positions of 220,364 shares during the same period.